AVAjay Vora

Ajay Vora

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ajay Vora has a total of 353 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reduced-intensity reinduction for children and young persons with relapsed acute lymphoblastic leukemia

    by Angus Hodder, Avijeet Mishra, Amir Enshaei, Susan Baird, Kaljit Bhuller, Anna Castleton, Katherine Clesham, Philip Connor, Ismail Elbeshlawi, Michael Gattens, et al.

  • Vincristine-Induced Neuropathy in UKALL 2011: Effects of Vincristine/Dexamethasone Pulse Omission and Prospective Gait Outcomes

    by Lucy Alderson, Lucy Waller, Mario Cortina-Borja, Vickyanne Carruthers, David Jamieson, John Moppett, Sheena Guram, Rachael Hough, Amy Kirkwood, Pam Kearns, et al.

    PURPOSE: Vincristine-induced peripheral neuropathy (VIPN) is a frequent, disabling complication of ALL therapy, yet its trajectory and risk factors remain incompletely defined. We prospectively evaluated VIPN, focusing on the impact of omitting vincristine/dexamethasone maintenance pulses and the utility of gait analysis as a functional end point. METHODS: This substudy was embedded within UKALL 2011. In all, 96 participants were enrolled; of these, 67 completed sufficient longitudinal neuropathy assessments without relapse and were included in the primary analyses, and 39 were randomly assigned to maintenance vincristine/dexamethasone pulses or no pulses. Participants age ≥5 years underwent Total Neuropathy Score–Pediatric Vincristine Revised (TNS-PVr) assessments at predefined time points from baseline to end-of-treatment. In addition, 46 participants underwent gait analysis using the GAITRite walkway, standardized to age- and sex-matched norms. Mixed-effects models estimated incidence rate ratios (IRRs) for neuropathy burden and explored pharmacogenomic associations. RESULTS: VIPN peaked after delayed intensification (51% with clinically significant neuropathy; TNS-PVr ≥5), improved during maintenance, and persisted in 16% at therapy completion. Gait analysis showed significantly reduced velocity, cadence, and step length versus norms (step length, –0.95 [95% CI, –1.14 to −0.76]; P < .001), with only partial recovery. Neuropathy burden increased with more-intensive vincristine therapy (IRR, 2.18 [95% CI, 1.07 to 4.42]; P = .032) and was reduced by omission of vincristine/dexamethasone pulses (IRR, 1.39 [95% CI, 1.06 to 1.84]; P = .019). Pharmacokinetics showed wide variability but no relationship to neuropathy. Pharmacogenomics revealed modest associations between neuropathy and single nucleotide polymorphisms associated with ABCB1 and SNU13 genes. CONCLUSION: VIPN is common, peaks during intensive phases, and persists in a minority at therapy completion. Our results provide randomized evidence that pulse omission reduces neuropathy burden, whereas gait analysis offers an objective end point to guide future ALL protocols and survivorship assessment.

  • Open Access

    Identification of favorable subgroups of childhood high-hyperdiploid acute lymphoblastic leukemia in a modern therapy era – A retrospective international study of 3,231 patients

    by Andishe Attarbaschi, Amir Enshaei, Saskia Sonnenberg, Chloé Arfeuille, Draga Barbaric, Lena Behrmann, Nicole Bodmer, Judith Boer, Myriam Campbell, Gunnar Cario, et al.

    B-cell acute lymphoblastic leukemia (B-ALL) with high-hyperdiploidy (HHD) represents the most prevalent genetic subtype of childhood ALL. This retrospective international study aimed to identify the HHD subgroup(s) having both the highest proportion of B-ALL cases and the best outcome.Data from 11,530 B-ALL patients, including 3,231 with HHD-B-ALL, treated between 1998 and 2018 in eight trials from seven international Berlin-Frankfurt-Münster Group members were analyzed. Eight HHD subgroups – including double and triple trisomies, trisomy 18, UK-good-risk (UK-GR) profile, and four different modal chromosome number (MCN) categories – were evaluated for 5-year event-free survival (EFS), overall survival, and relapse. Each subgroup was ranked by outcome measures and prevalence within the B-ALL trial cohorts.HHD frequency ranged from 19–35%. MCN 54–67 and UK-GR profile achieved the lowest overall ranking scores corresponding to the largest (up to 28% for MCN 54–67 and 26% for UK-GR among total B-ALL trial cohorts) and best HHD subgroups (EFS ranged from 80.5–92.8% for MCN 54–67 and 80.5–93.5% for UK-GR).Both an MCN of 54–67 and UK-GR profile define large, reproducible subgroups of HHD B-ALL with good prognosis. They represent strong candidates for risk-stratification of treatment de-intensification trials in the modern immunotherapy era.

  • Top Cited Papers
    Open Access

    High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011

    by Amy A. Kirkwood, Nicholas Goulden, John Moppett, Sujith Samarasinghe, Rachael Hough, Clare Rowntree, Sarah Lawson, Pam Kearns, Anna Lawson, Ajay Vora

    PURPOSE: UKALL 2011 randomly assigned children and young adults (younger than 25 years) with ALL or lymphoblastic lymphoma. The aims were to reduce induction toxicity (randomization 1 [R1]), CNS relapse risk (randomization 2 [R2]–interim maintenance [R2IM]), and maintenance morbidity (R2pulses). METHODS: R1 compared induction dexamethasone (dex) for 28 days (6 mg/m 2 ; standard) with 14 days (10 mg/m 2 ; short). R2 was a factorial randomization resulting in four arms: high-dose methotrexate (HDM) with pulses, HDM without pulses, standard interim maintenance (SIM) with pulses (standard of care), and SIM without pulses. The primary end points were reduction in steroid-related toxicity (R1), CNS relapse rate (CNSR, R2IM), and bone marrow relapse rate (BMR, R2pulses; ALL only, noninferiority margin 5%). Event-free survival (EFS) was an additional primary end point for both randomizations. RESULTS: Of 2,750 eligible patients registered between April 2012 and December 2018, 1,902 were randomly assigned to R1 and 1,570 to R2. Median follow-up is 99 (R1) and 87 months (R2). There were no differences in steroid-related toxicity between short and standard dex (23.8% v 25.5%; P = .41) and CNSR between SIM and HDM (0.98 [95% CI, 0.65 to 1.49]; P = .94; 5-year rates: SIM 5.3% and HDM 5.5%). EFS was no different between R1 and R2IM arms. BMR in the no pulses arm was noninferior (+1.7% increase at 5 years [95% CI, –1.5 to 4.1]; hazard ratio [HR], 1.19 [95% CI, 0.87 to 1.62]; P = .27). Although the EFS in the no pulses arm was inferior (1.34 [95% CI, 1.05 to 1.73]; P = .021), this was not significant for relapse (HR, 1.24 [95% CI, 0.96 to 1.62]; P = .10). CONCLUSION: Shorter duration of induction dex does not reduce steroid-related toxicity and HDM does not improve CNSR within a UKALL treatment backbone. Omission of pulses is noninferior for BMR.


  • Open Access

    Benefits for children with suspected cancer from routine whole-genome sequencing

    by Angus Hodder, Sarah M. Leiter, Jonathan Kennedy, Dilys Addy, Munaza Ahmed, Thankamma Ajithkumar, Kieren Allinson, Phil Ancliff, Shivani Bailey, Gemma Barnard, et al.

    Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n = 152 from a hematology center, n = 130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases. Furthermore, WGS faithfully reproduced every standard-of-care molecular test (n = 738) and revealed several previously unknown genomic features of childhood tumors. We show that WGS can be delivered as part of routine clinical care to children with suspected cancer and can change clinical management by delivering unexpected genomic insights. Our experience portrays WGS as a clinically impactful assay for routine practice, providing opportunities for assay consolidation and for delivery of molecularly informed patient care.


  • Open Access

    ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?

    by Anna Østergaard, Marta Fiocco, Hester de Groot-Kruseman, Anthony V. Moorman, Ajay Vora, Martin Zimmermann, Martin Schrappe, Andrea Biondi, Gabriele Escherich, Jan Stary, et al.

    Recent trials show 5-year survival rates >95% for ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL). Since treatment has many side effects, an overview of cumulative drug doses and intensities between eight international trials is presented to characterize therapy needed for cure. A meta-analysis was performed as a comprehensive summary of survival outcomes at 5 and 10 years. For drug dose comparison in non-high risk trial arms, risk group distribution was applied to split the trials into two groups: trial group A with ~70% (range: 63.5–75%) of patients in low risk (LR) (CCLSG ALL2004, CoALL 07-03, NOPHO ALL2008, UKALL2003) and trial group B with ~45% (range: 38.7–52.7%) in LR (AIEOP-BFM ALL 2000, ALL-IC BFM ALL 2002, DCOG ALL10, JACLS ALL-02). Meta-analysis did not show evidence of heterogeneity between studies in trial group A LR and medium risk (MR) despite differences in treatment intensity. Statistical heterogeneity was present in trial group B LR and MR. Trials using higher cumulative dose and intensity of asparaginase and pulses of glucocorticoids and vincristine showed better 5-year event-free survival but similar overall survival. Based on similar outcomes between trials despite differences in therapy intensity, future trials should investigate, to what extent de-escalation is feasible for ETV6::RUNX1 ALL.


  • Top Cited Papers

    Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL

    by Angus Hodder, Avijeet K Mishra, Amir Enshaei, Susan Baird, Ismail Elbeshlawi, Denise Bonney, Katherine Clesham, Michelle Cummins, Aditi Vedi, Brenda Gibson, et al.

    PURPOSE: We tested whether blinatumomab (Blina) is effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons (CYP) with B-ALL who were chemotherapy-intolerant or chemotherapy-resistant. METHODS: Data were collected for consecutive CYP (age 1-24 years) with Philadelphia chromosome–positive or Philadelphia chromosome–negative B-ALL who received Blina as first-line therapy. Blina was given as replacement for postremission intensive chemotherapy to patients with chemotherapy intolerance or resistance. Blina responders received further chemotherapy (Blin-CT) or first remission hematopoietic stem-cell transplant (Blin-HSCT) if indicated. Event-free survival (EFS) and overall survival (OS) of the Blin-CT group were compared with those of matched controls treated with standard chemotherapy in the UKALL 2003 trial. Events were defined as death, relapse, or secondary cancer. RESULTS: From February 2018 to February 2023, 105 patients were treated, of whom 85 were in the Blin-CT group and 20 were in the Blin-HSCT group. A majority of Blin-CT patients received Blina for chemotherapy intolerance (70 of 85, 82%), and the group had a higher-risk profile than unselected patients with B-ALL. Blina was well tolerated with only one patient having a grade 3/4–related toxicity event, and of the 60 patients who were minimal residual disease–positive pre-Blina, 58 of 60 (97%) responded. At a median follow-up of 22 months, the 2-year outcomes of the 80 matched Blin-CT group patients were similar to those of 192 controls (EFS, 95% [95% CI, 85 to 98] v 90% [95% CI, 65 to 93] and OS, 97% [95% CI, 86 to 99] v 94% [95% CI, 89 to 96]). Of the 20 in the HSCT group, three died because of transplant complications and two relapsed. CONCLUSION: Blina is safe and effective in first-line treatment of chemotherapy-intolerant CYP with ALL.


  • Open Access

    Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL

    by David O’cOnnor, Melvin Joy, Amir Enshaei, Amy Kirkwood, Pamela R. Kearns, Sujith Samarasinghe, John Moppett, Anthony V. Moorman, Ajay Vora